At 21.5% CAGR, CBD Oil Market Size & Share | Cannabidiol Oil Industry Report, 2020-2025 | Covid-19 Impact Analysis

In its latest report on CBD Oil Market provides a concise analysis of the recent market trends. The report further includes statistics, market forecasts and revenue estimations, which in addition highlights its status in the competitive domain as well as expansion trends adopted by major industry players.

Cannabidiol Oil (CBD Oil) Market: Global Market Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025.Cannabidiol Oil Market is valued at USD 23.37 Million in 2018 and expected to reach USD 1068.54 Million by 2025 with the CAGR of 21.5% over the forecast period.

Get sample of this report.

The detailed market intelligence report on the Global Cannabidiol Oil (CBD Oil) Market applies the most effective of each primary and secondary analysis to weighs upon the competitive landscape and also the outstanding market players expected to dominate Global Cannabidiol Oil (CBD Oil) Market place for the forecast 2019- 2025.

FDA Advances Work Related To Cannabidiol Products With Focus On Protecting Public Health, Providing Market Clarity

DISTRICT OF COLUMBIA: Over the past year, the U.S. Food and Drug Administration has embarked on a comprehensive evaluation of cannabidiol (CBD) products, with a focus on educating the public about the risks and unknowns of these products, gathering the science needed to better understand both these safety concerns and potential benefits to inform our regulatory approach, as well as taking steps when necessary to address products that violate the law in ways that raise a variety of public health concerns.

Today, we are providing updates on our efforts in this area, including several new steps in areas of education, research and enforcement with the ultimate goal of continuing to protect the public health and working to provide market clarity.

Educating the Public About Potential Risks of Using CBD

We’re seeing CBD being marketed in a number of different products, such as oil drops, capsules, syrups, food products, such as chocolate bars and teas, cosmetics and other topical lotions and creams, as well as products marketed for pets and other animals – and we understand consumers are seeking out these novel products for a variety of perceived health-related or other reasons.

But as the agency has stated before, we are concerned that some people wrongly think that the myriad of CBD products on the market have been evaluated by the FDA and determined to be safe, or that using CBD ‘can’t hurt.’ Aside from one prescription drug approved to treat two rare, severe pediatric epilepsy disorders, no other CBD products have been evaluated or approved by the FDA.

We remain focused on educating the public about the number of questions that remain regarding CBD’s safety. There may be risks that need to be considered before using CBD products outside of the monitored setting of a prescription from your health care provider.

In particular, the agency recently updated the public on concerns about potential harm from CBD products, including potential liver injury, interactions with other drugs and male reproductive toxicity, as well as side effects such as drowsiness. In addition, there is still much we do not know about other potential risks. For example, other than the approved prescription drug, we know little about the potential effects of sustained and/or cumulative use of CBD, co-administration with other medicines, or the risks to vulnerable populations like children, pregnant and lactating women, the elderly, unborn children and certain animal populations. This does not mean that we know CBD is unsafe to these populations or under these circumstances, but given the gaps in our current knowledge, and the known risks that have been identified, we also are not at a point where we can conclude that unapproved CBD products are safe for use. We encourage Americans to consult with their health care providers before using CBD products.

We will continue to expand our educational efforts on this front. This includes consumers broadly, specific populations where there are additional, important health considerations, as well as health care professionals who must understand these risks when talking to their patients. We will also continue to update our online resources for consumers, researchers and industry, as well as sustain multiple lines of communication with Congress, industry, researchers and our regulatory partners at the federal, state, local, territorial, tribal and international levels to share and collect needed information and hear a variety of perspectives.

Closing Knowledge Gaps in Both Safety and Potential Benefits

The marketplace for CBD-containing products is quickly evolving and it is critical that we work together with stakeholders and industry to develop high-quality data to close the knowledge gaps about the science, safety and quality of many of these products, as well as further evaluate any potential benefits outside of the one FDA-approved drug product to treat two rare, severe pediatric epilepsy disorders.

To address the questions and concerns we’ve already raised, we’re seeking reliable and high-quality data. This includes data on, among other things: the sedative effects of CBD; the impacts of long-term sustained or cumulative exposure to CBD; transdermal penetration and pharmacokinetics of CBD; the effect of different routes of CBD administration (e.g., oral, topical, inhaled) on its safety profile; the safety of CBD for use in pets and food-producing animals; and the processes by which “full spectrum” and “broad spectrum” hemp extracts are derived, what the content of such extracts is, and how these products may compare to CBD isolate products.

Given the importance of answering these questions, we’re exploring a number of ways to address the data gaps as quickly as possible. This includes encouraging, facilitating and initiating more research on CBD, providing venues for industry and researchers to share new data with the agency and identifying opportunities to further collaborate with our federal partners at Centers for Disease Control and Prevention, Substance Abuse and Mental Health Services Administration and National Institute on Drug Abuse on this important issue.

Importantly, the Agriculture Improvement Act of 2018 – which, among other things, changed federal law so that cannabis and cannabis derivatives with very low levels of the psychoactive intoxicating component of cannabis, delta-9 tetrahydrocannabinol (THC) are no longer controlled substances – has opened significant new opportunities for research, and as that body of research develops and grows, there will be considerably more information available. In particular, there’s been an increased interest in drug development from CBD and other compounds found in cannabis and we are working to support drug development as much as possible.

First, given all the research and activity in this space, we are taking new steps to provide a public and transparent way for stakeholders to provide new and emerging information to us in real time as it becomes available. To this end, in the coming days we are re-opening the public docket we established for our May 2019 public hearing. The docket provides a valuable conduit for submission of scientific data on CBD to the agency, so we have decided to extend the comment period indefinitely to allow the public to comment and to share relevant data with the agency. As the agency continues to move forward to explore viable pathways for CBD products outside the drug context, this extension will allow stakeholders to continue to provide relevant data as research in this area evolves.

This docket also includes a mechanism for a stakeholder to submit data or information that the stakeholder believes to be confidential. We hope that this will enable responsible industry participants, academic researchers, and other stakeholders to share relevant information with the FDA – including information about specific products, which could help inform appropriate regulatory steps.

We also are working to generate data to help inform our work in this area. For example, the FDA’s Office of the Chief Scientist recently awarded a grant to the FDA’s National Center for Toxicological Research to conduct a study to better understand the effects of CBD exposure during pregnancy. Additionally, we’ve initiated a research study in partnership with the University of Mississippi to evaluate the levels of CBD and THC in a sample of cosmetic products to assess sensitization of THC and CBD topically, and dermal penetration.

As data become available that are high-quality, reliable and relevant to our evaluation of CBD products that fall under the FDA’s purview, we will be able to refine – and, perhaps in some cases, revise – our thinking and approaches.

Monitoring the Marketplace with a Focus on Greatest Risk to Public Harm

As we work to educate the public and close the knowledge gaps to further guide our approach to CBD products, we will continue to monitor the marketplace and take appropriate action against unlawful CBD products that pose a risk of harm to the public.

We have seen many CBD products being marketed with claims of therapeutic benefit, such as treating or curing serious diseases such as cancer and Alzheimer’s disease, or other drug claims, without having gone through the drug approval process. The proliferation of such products may deter consumers from seeking proven, safe medical therapies for serious illnesses – potentially endangering their health or life.

We also have serious concerns about products that put the public at risk in other ways. For example, we are aware of the risks posed by product contaminants such as heavy metals, THC or other potentially harmful substances. We also have significant concerns about products marketed with false claims or statements such as omitted ingredients, incorrect statements about the amount of CBD, products marketed for use by vulnerable populations like children or infants, and products that otherwise put the public health at risk.

As we move forward, we are currently evaluating issuance of a risk-based enforcement policy that would provide greater transparency and clarity regarding factors the agency intends to take into account in prioritizing enforcement decisions. Any enforcement policy would need to further the goals of protecting the public and providing more clarity to industry and the public regarding the FDA’s enforcement priorities while we take potential steps to establish a clear regulatory pathway.

Conclusion

Our ongoing efforts related to CBD, including the steps we’re announcing today, are in line with our mission to protect the public, foster innovation and promote consumer confidence. We recognize the significant public interest in CBD and we must work together with stakeholders and industry to develop high-quality data to close the substantial knowledge gaps about the science, safety and quality of many of these products. We are committed to working efficiently to further clarify our regulatory approach to these products – as always, using science as our guide and upholding our rigorous public health standards.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Asheville Hemp Project Launches CBD Infused Gum

First Product from Asheville Hemp Project Brand Highly Efficiency Delivery Method

NORTH CAROLINA: Asheville Hemp Project (AHP), an Asheville, NC-based hemp cultivator, is unveiling its new CBD Mint Gum. The launch marks the first consumer product for the brand, with other SKU’s in the pipeline. Asheville Hemp Project aims to connect consumers to the source of the natural plant, and their own inner nature.

The brand reminds us of the calming effect that nature provides, with a view through an open-slatted tobacco barn imprint. AHP selected gum as the first product to introduce because of its super-efficient delivery of CBD. Each piece of AHP’s CBD Mint Gum contains 10 milligrams of CBD and comes in a convenient foil pack that maximizes freshness and improves product protection and dispensing. AHP Gum is available for sale in the U.S. via the Company’s online store and at retailers including boutique food markets, CBD dispensaries, gas stations and smoke shops, and soon in sports emporiums and golf pro shops. A single pack containing 8 pieces sells for $19.90 online.

Leslie Hoffman, co-founder of AHP, stated, “This is our first consumer product, and we are excited about its potential. It delivers hemp-derived cannabinoids most efficiently through mucosa glands being activated by the chewing of the gum. Our gum enhances wellness for anyone who can benefit from CBD – and delivers it in a refreshing ‘normal’ format that is as discreet as it gets.”

CBD Mint Gum

Users include those with busy modern (and sometimes stressful) lives or those who need to lessen arthritis and joint pain or need better sleep. Sports aficionados might find that they can focus more intently or diminish the inflammation that sometimes follows a strenuous workout.”

Hoffman continued, “We intend to follow up with the launch of our CBD premium pre-rolls which will be unfiltered to ensure the consumer ingests the cannabinoids. Further, we have plans for releasing a CBD tincture. The number of potential products is enormous.”

Transitioning to the 21st Century Economy

Hoffman, whose pedigree in the cannabis industry includes farming, a hemp fashion business, and work in medical cannabis, formed Asheville Hemp Project in 2017 with co-founder, Scott Brinkley, a scientist and grower. Hoffman was a pioneer in sustainability and was previously a designer and builder of green construction projects.

The two saw an opportunity in North Carolina where tobacco had once been king. The agricultural and processing infrastructure for tobacco is well-suited to the cultivation and production of hemp.

Hoffman said, “The equipment and buildings needed to grow and dry the leaves, and the factories for rolling cigarettes already exist and are under-utilized. The workforce has the requisite skills to produce high quality products. The difference is the plant. Hemp is vastly more useful than tobacco. We aim to share a point of view, a connection to nature, and our understanding of the plant and its many uses. And so, we expanded our activities beyond the farm.”

She added, “Asheville has a reputation as an epicenter for craft cuisine and breweries. The region’s old tobacco farms are benefitting as they are revitalized by a thriving hemp farming community. Our brand’s tagline is Look Homeward, a reference to Thomas Wolfe’s famous book written in Asheville and set there, called Look Homeward, Angel. We believe this is the right business, with the right values, operating in the right place at the right time.”

Asheville Hemp Project’s base is a 23-acre hemp farm outside of the small city of Asheville, North Carolina nestled between the Blue Ridge and Great Smoky Mountains.

“This is where our experience grows, thoughts and ideas turn into new product innovations,” Brinkley states. “We work with other local farmers and processors in developing new products and establishing new markets. The vacuum tobacco left behind provides an atmosphere for us to all work together to build the hemp industry. As a community, we can do more and do it better.”

FDA Warning Letters And Test Results For Cannabidiol-Related Products

MJLegal

DISTRICT OF COLUMBIA: Over the past several years, FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD).

As part of these actions, FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. It is important to note that these products are not approved by FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Consumers should beware purchasing and using any such products.

FDA WARNING LETTTERS

FDA, FTC Warn Company Marketing Unapproved Cannabidiol Products With Unsubstantiated Claims

FDA is also working quickly to evaluate regulatory policies related to cannabis and cannabis-derived ingredients like CBD

DISTRICT OF COLUMBIA: The U.S. Food and Drug Administration and the Federal Trade Commission posted a joint warning letter to Rooted Apothecary LLC, of Naples, Florida, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat teething pain and ear aches in infants, autism, attention-deficit/hyperactivity disorder (ADHD), as well as Parkinson’s and Alzheimer’s disease, among other conditions or diseases.

“Cannabis and cannabis-derived compounds are subject to the same laws and requirements as FDA-regulated products that contain any other substance. We are working to protect Americans from companies marketing products with unsubstantiated claims that they prevent, diagnose, treat, or cure a number of diseases or conditions. This is especially concerning when companies are peddling unproven CBD products for use in vulnerable populations like infants and children,” said Acting FDA Commissioner Ned Sharpless, M.D. “We’ve sent numerous warning letters that focus on matters of significant public health concern to CBD companies, and these actions should send a message to the broader market about complying with FDA requirements. As we examine potential regulatory pathways for the lawful marketing of cannabis products, protecting and promoting public health through sound, science-based decision-making remains our top priority. We appreciate the FTC joining us on these and other actions to protect consumers from fraudulent CBD products.”

As described in the warning letter issued to Rooted Apothecary, the company used product webpages, through its online store and social media websites, to make unfounded claims about its CBD products, and some of the products were also unlawfully marketed as dietary supplements. The agency has determined that CBD products cannot be marketed as dietary supplements.

Examples of the unsupported claims made by the company include:

  • “Instead of synthetic chemical[s] that can have safety concerns, this blend uses the best of nature to help calm the inflammation and pain of teething, while also promoting sleepiness for your little one.”
  • “No matter what age, ear aches are a terrible, no good way to live each day! Our main priority was safety, effectiveness . . . as we formulated this for the entire family including our precious little ones. When the pain is bad, this roller goes to work for soothing pain, inflammation, and to battle against the bacterial/viral critters to blame.”
  • “Increasing evidence suggests that CBD oil is a powerful option for pain . . . anxiety . . . and autism . . . It seems like an attractive and safe option for children.”
  • “CBD oil may have neuroprotective properties and may protect against neurological conditions, such as Parkinson’s and Alzheimer’s disease.”
  • “[P]ossible uses for CBD include helping with skin problems such as acne, autism, ADHD, and even cancer. It’s often used in conjunction with traditional treatments to provide extra help. Children can use high amounts of CBD safely and without any risk.”

Additionally, under the Federal Trade Commission Act, it is unlawful to advertise that a product can prevent, treat, or cure human disease unless the advertiser possesses competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. The FTC is concerned that one or more of the efficacy claims cited may not be substantiated by competent and reliable scientific evidence. These products are also misbranded under the Federal Food, Drug, and Cosmetic (FD&C) Act, because the products’ labels and product information fail to include adequate directions for use. Drugs in the United States must contain directions explaining how a consumer can use a drug safely for its intended purpose. Under the law, there is an exemption for this labeling requirement for prescription drugs that have FDA-approved applications in effect. However, none of Rooted Apothecary’s products are FDA-approved.

The FDA and FTC have requested responses from Rooted Apothecary within 15 working days stating how the company will correct the violations. Failure to correct the violations promptly may result in legal action, including product seizure and/or injunction. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or administrative cease and desist order, and an order also may require that a company pay back money to consumers.

The FDA continues to be concerned about the proliferation of products claiming to contain CBD that are marketed for therapeutic or medical uses that have not been approved by the agency. The FDA approval process ensures that drugs on the market are safe and effective for their intended therapeutic uses. CBD is marketed in a variety of product types, such as oil drops, capsules, syrups, teas and topical lotions and creams. The FDA has not approved any CBD products other than one prescription human drug product to treat rare, severe forms of epilepsy. There is very limited information for other marketed CBD products, which likely differ in composition from the FDA-approved product and have not been evaluated for potential adverse effects on the body.

The FDA continues to explore potential pathways for various types of CBD products to be lawfully marketed. An important component of this work is obtaining and evaluating information to address outstanding questions related to the safety of CBD products while maintaining the FDA’s rigorous public health standards.

“The FDA is working quickly to further clarify our regulatory approach for products containing cannabis and cannabis-derived compounds like CBD while using all available resources to monitor the marketplace and protect public health by taking action as needed against companies,” said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. “We recognize that there is significant public interest in cannabis and cannabis-derived compounds; however, we must work together to fill in the knowledge gaps about the science, safety and quality of many of these products. We are committed to advancing our regulation of these products through an approach that, in line with our mission, prioritizes public health, fosters innovation and promotes consumer confidence.”

Unlike drugs approved by the FDA, the manufacturing process of unapproved CBD products has not been subject to FDA review as part of the drug approval process. Further, there has been no FDA evaluation of whether these products are effective for their intended use, what the proper dosage is, how they could interact with FDA-approved drugs, or whether they have dangerous side effects or other safety concerns. Consumers may put off getting important medical care, such as proper diagnosis, treatment and supportive care due to unsubstantiated claims associated with CBD products. For that reason, it’s important that consumers talk to a health care professional about the best way to treat diseases or conditions with existing, approved treatment options.

The FDA has previously sent warning letters to other companies illegally selling CBD products that claimed to prevent, diagnose, treat or cure serious diseases, such as cancer. Some of these products were in further violation of the FD&C Act because they were marketed as dietary supplements or because they involved the addition of CBD to food.

The FDA encourages health care professionals and consumers to report adverse reactions associated with these or similar products to the agency’s MedWatch program.

The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

 

The Benefits Of CBD Oil For Sleep Disorders And Insomnia

One of the most important components of life is sleep. The way we sleep at night largely influences the behavior and performance we provide the next day. More and more people are suffering from a form of chronic sleep disorder. Specialists believe that certain medication can  contribute to insomnia, especially as this disorder is a frequent side effect of antidepressants.

On the other hand, people who are taking sleeping pills, to get rid of insomnia, can become addicted to these drugs. This state of dependence appears when the treatment is stopped. Symptoms like tremors, nausea, anxiety, changes in blood pressure, muscle cramps may then occur.

Since drugs generate addiction and can lead to abuse, people are looking for natural options to minimize the negative effects. In this sense, cannabidiol has become a viable medical alternative. Here is how CBD is not only a healthy alternative to sleeping pills but it can counteract many factors that cause sleep disturbances.

What is Insomnia?

Insomnia is the sensation of inadequate or poor repose due to problematic sleep, frequent night awakening with difficulty in falling asleep again.

Insomnia is classified as:

  • Transient (short-term) – lasting from one night to a few weeks;
  • Intermittent (appears and disappears) – where the episodes appear from time to time;
  • Chronic (constant) – insomnia occurs in most nights, at least three times a week for more than a month.

Insomnia may occur due to emotional, neurological or medical disorders as well as a result of stimulant medications or alcohol/drug addiction. 

insomnia too

What Illnesses Can Insomnia Hide?

In most cases, insomnia is based on psychiatric pathology, ie neurosis (depression, anxiety) or psychosis (schizophrenia and related disorders). Insomnia also occurs in thyroid disorders, alongside depression and appetite disorders.

Insomnia may appear in patients with adrenal gland disorders, as well as patients with advanced cirrhosis when hepatic encephalopathy occurs. Last but not least, this disease occurs in patients with cardiac pathology, especially due to decompensation in the evening or at night.

How Does CBD Work?

CBD works through the endocannabinoid system (ECS). In our body, this system produces its own cannabinoids. ECS regulates processes such as our mood and appetite, as well as our perception of pain.

CBD interacts with the endocannabinoid system and its receptors having numerous beneficial effects as research results suggest.

CBD Oil

Image source: Pexels.com

The Effects of CBD on Sleep

CBD is a constituent of the plant called cannabis. Another constituent of this plant is THC. Both substances are known for their beneficial effects. However, THC also has a psychoactive effect, unlike CBD. Hemp plants contain a high CBD concentration.

Several studies have shown that CBD can have a medicinal effect on a wide range of health problems. One of these problems is insomnia. CBD not only makes sleeping easier but also influences the sleep cycle.

Sleep divides into several cycles with different phases. Insomnia occurs during the rapid eye movement (REM) stage, called REM parasomnia. In this phase, active behavior and nightmares will take place during dreams. This is a category of sleep disorders that involves behaviors, emotions and abnormal movements. It is also characterized by loss of muscles’ capacity to relax during REM sleep.

Cannabidiol has strong anxiolytic, anticonvulsant and sedative effects. CBD oil has the ability to control these disturbing symptoms because it directly affects CB1 receptors in the brain, an important receptor that is responsible for multiple actions of the central nervous system.

In addition, CBD decreases the duration of REM sleep. By reducing this phase, people dream less, memory improves and symptoms of depression are lowered. Blood tests have shown that CBD oil influences dopamine levels in the blood during sleep. This leads to a better, relaxed sleep alongside lower destructive behavior.

In sleep disturbance, the same component called CBD, by its anxiolytic effect, blocks anxiety states induced in REM sleep state, which makes a person suffering from this disorder have a longer sleeping time; therefore, recover fast from damages provoked by previous insomnia episodes.

Recommended CBD Oil Dosage in Sleeping Disorders?

The first thing to look for, when decided to consume CBD oil, is its purity. This applies in any case, regardless of the medical disorder encountered. If it is not in its pure state, containing 100% CBD oil, this treatment may have weaker results. Moreover, when it is not in a pure state, this oil may comprise other chemicals which promote allergies.

Hellomello.life offers lab-tested, 100% natural CBD oil which may come in handy in treating sleep disorders and insomnia. Unlike other medical treatments, this CBD oil does not give addiction and does not have other side effects on brain chemistry, in neither short or long-term.

For sleep disorders, the recommended CBD oil dosage shall fall between 40 mg-160 mg of CBD taken orally. The exact amount taken depends on the user’s body weight and tolerance, as well as the concentration of CBD per ml of oil. The higher the body weight, the greater is the dosage of CBD oil.

In some cases, users develop a tolerance to the consumption of CBD oil, meaning that once ingested effects take longer to appear. In this case, it is advisable to increase the usual dosage.

Final Thoughts

Cannabidiol (CBD) is a component of Cannabis sativa plant that has an extensive range of potential beneficial effects in neuropsychiatric and other disorders. Insomnia is among disorders that finds its cure in CBD oil.

Sleep is very important for the body’s recovery and if this becomes insufficient it can affect your health. The main cause of insomnia today stays the stress, which in the long run remains harmful to the body.

Among the most common reasons for using CBD oil is the effect of relieving stress and anxiety. Cannabidiol has great efficacy in relaxing the mind, reducing stress and inducing calmness, being a good solution to combat insomnia and sleep disorders.

7 Best CBD Gummies To Purchase This Year

It’s hard not to notice how popular CBD has become recently. People commonly ingest it through oils and tinctures, but like marijuana, there are other ways to reap its significant health benefits (that do not come with feeling high).

One of these ways is through edibles. Instead of marijuana cookies you may be familiar with, CBD is often infused into candy-like gummies. These gummies can pack a potent punch but have the benefit of being inconspicuous: if you feel yourself feeling anxious or in pain throughout the day, you can take them as-needed, even at work or in public.

Not all CBD products are made the same, though. The cannabidiol industry is largely unregulated, so there is no overarching governing body holding CBD companies to high standards or vigilantly enforcing them (the FDA has only sent warning letters to rule breakers). It’s imperative to purchase from a reputable company, and you should keep your interests in mind when shopping (how much CBD do you need? How often will you take it? How soon do you need it? What flavors do you prefer, and what does your budget allow for)? Here are a few of the best CBD gummies to check out this year:

Verma Farms CBDVerma Farms

If you want delicious-tasting CBD gummies, then Verma Farms is worth a look. This brand offers multiple concentrations (such as 10, 12.5, or 21 mg of cannabidiol per candy) and flavors, including Blueberry Wave, Island Apple, and Beary Beach. Though experts say that CBD works best in conjunction with a little THC—and the federal legal limit is .3 percent—Verma’s products are made without THC just in case you are nervous about it showing up on a drug test. The company even offers dried CBD fruit so that you can still get chewy deliciousness if traditional gummies are not your thing.

CBDfx 

CBDfx offers a broad array of CBD products. Many of its gummies also include a few special extra ingredients, such as melatonin for sleep and superfoods like spirulina and turmeric for reducing inflammation. What’s great about CBD gummies is that no matter what you use them for, all you need to do is pop one in your mouth and chew—much more efficient than setting up a vape pen or dealing with the earthy taste of many unflavored oils.

CBDistillery 

CBDistillery sources local hemp from Colorado and extracts cannabidiol from a CO2 process. Their fruity gummies taste delicious and use high-quality ingredients. To make things better, they are vegan and are affordably priced. Any CBD company that knows what it’s doing will have its products tested with third party labs for things like purity and potency, and CBDistillery publishes those results on its website. Many CBD companies do this, like Verma Farms, but not nearly enough—having an easily accessible Certificate of Analysis with test results online is a marker of a legitimate CBD business that is transparent about its products.

Green Roads

Green Roads is one of the more famous CBD brands out there. Not only does it have tasty CBD gummies, its candies come in fun shapes like bears, fruit bites, toads, and “froggies.” They come in a few concentrations from 10 to 25 mg and even include sour flavors. CBD products can taste earthy, but Green Roads’ products ensure that not only do you enjoy the benefits of CBD, you enjoy the actual experience of taking it.

Charlotte's Web Gummies Charlotte’s Web

Charlotte’s Web is another leading CBD brand. What’s intriguing about its gummies, though, is that each of them have a different formula according to its intended use. Its sleep gummies, for instance, include melatonin, and its “calm” variety incorporates L-theanine and lemon balm. Likewise, its “recovery” label is made with turmeric and ginger to support joint and overall health. It’s packages also come in packs of 60, which should last you around two months.

Happy Hemp

When you think of gummies, you probably do not only think of fruit bites or bears—you also imagine gummy worms, rings, ribbons, sours, and more. Happy Hemp offers all of them, including CBD strawberry licorice. It’s prices range from as little as $23.99 to as much as $99.99, but that’s because the company offers packages available in 250, 750, 1500, and 300 mg strengths. With Happy Hemp’s diverse variety, taking CBD will never be boring.

CBD Infusionz GummiesCBD Infusionz

CBD Infusionz, as its names suggests, infuses CBD into a multitude of products, such as gum, honey, chocolate, hard candy, and more—and of course, an assortment of gummies. CBD Infusionz also gives you the option of choosing between full spectrum or THC, so you can benefit from more potent properties or not worry about THC showing up on a drug test.

CBD is a sizable market, and there’s a gummy out there for anyone who wants to try cannabidiol with a bit of candied fun. Which gummy sparks your interest?

Daytrip Expands CBD Sparkling Water Line To New York And New Jersey Markets

Daytrip to introduce THC sparkling water line by end of year

NEW YORK:  Daytrip, the leading cannabis lifestyle brand announced today its expansion into the New York and New Jersey area. After an initial launch in June 2019 across California, Washington, Oregon and Michigan, Daytrip is staking its claim in the metropolitan area as the premier CBD beverage.

Daytrip’s product line will now be available in several retailers across the metropolitan area including Fairway Market, Food Emporium, ShopRite, Westside Market and many others, available in four natural fruit flavors: Cherry, Coconut Pineapple, Lemon Lime and Tangerine.

“The initial reaction to our launch in June has been overwhelmingly positive, and we’re pleased to deliver on our customer’s desires and formally introduce Daytrip to New York and New Jersey, where the demand for natural, premium quality CBD is strong” said Shawn Biega, CEO Daytrip. “Our sparkling water line is only the beginning. In short order, we plan to introduce a series of food & beverage consumables to the CBD market and establish ourselves as a true leader in the space.”

“As the CBD market continues to evolve at a rapid pace, now is the ideal time to introduce Daytrip to an incredibly important market for our future success,” said Joey Cannata, President Daytrip. “What people love about our product is that there’s no sugar, no sweeteners — just a natural flavor that fits in with the spontaneous adventurous lifestyle we see in New York City and New Jersey.”

By the end of the year, Daytrip plans to introduce a THC infused sparkling water line in California, as well as other food & beverage products driven by Daytrip’s proprietary Foliole Nexus Technology that enhances the bioavailability to the CBD ingredient aiding with absorption for a more instant effect.

Each Daytrip beverage contains five calories and includes 10 mg of CBD per can, retailing at $4.99 in the general market and $59.00/12 pk on the first order, available at wearedaytrip.com.

The product is currently available online at www.wearedaytrip.com, as well as distributors across New York, New Jersey, California, Oregon, Michigan and Washington. For more information please visit www.wearedaytrip.com and follow us on Instagram @wearedaytrip.

 

4 Ways That CBD Can Help Pets As Well As People

You may know all about the benefits that CBD can bring to people. It’s been shown to help with numerous health issues. However, it’s not just people that can benefit from using CBD.

Pets can also benefit if their owners use CBD wholesale products to treat various conditions and psychological issues that animals can have. Let’s examine some of the ways that CBD can be helpful to pets.

Reducing stress and anxiety

There can be many times when pets become nervous, such as when there is thunder in the air. It’s not pleasant to see your pet distressed in this way. CBD can help with this.

It can also be used to help if your dog struggles when you are not at home. It can make it easier for them to deal with the issues they have with separation anxiety. This does not just make your dog happier, it can also help to reduce destructive tendencies that result from stress.

Helping with epilepsy

There are several medications available that can help animals that suffer from seizures. However, some of these medications can have harmful side effects. Just like it can in humans, CBD can help deal with seizures in pets.

Relieving chronic pain

CBD has been reported as being successful in helping relieve chronic pain in humans. It can also be useful in helping to treat pets that have pain which is associated with inflammatory conditions such as arthritis and issues with nerve pain.

Dealing with loss of appetite

It can be very stressful for you and your pet if they are not eating as they should. CBD can help improve your pet’s appetite, so that they begin to eat a healthy amount of food. It’s also been shown that CBD can help to relieve symptoms in pets that are suffering from nausea or vomiting.

Seeking advice from a vet

If you have a pet that you think could benefit from the use of CBD, you should think about consulting a vet. They can give you advice about how CBD can be integrated into a health care regime for animals. You should do this before taking any action, so that you know whether you are doing the right thing.

In summary

Although CBD was first identified in the 1940s, it’s only recently that research has started to show the benefits it can have for people. Now, it seems that people are not the only ones who can benefit from its use. The benefits can also be useful to pets.

This is why you should think about using CBD if your pet is experiencing certain issues. These issues can include anxiety, loss of appetite and chronic pain. If your pet is affected by any of these problems, you should speak to a vet about using CBD. On its own, or in conjunction with other treatments, it may be what you need to use in order to greatly improve the life of your pet.

 

 

 

 

 

 

 

 

 

 

Alternate Health Reports $1.9 Million Of Revenue In Q2 2019

CANADA: Alternate Health Corp., an international leader in CBD extraction, product development and distribution, has announced that the company generated $1.9 million in Q2 revenue.

“Alternate Health’s Q2 results represent just the beginning of our new strategic direction as we focus exclusively on the hemp-derived CBD industry and, especially, product development and distribution,” says Howard Mann, CEO of Alternate Health. “We have built a strong base to rapidly expand our hemp and CBD product lines and capture a larger share of this exciting market.”
 
The Company’s large year-over-year increase in revenue is tied to Alternate Health’s recent acquisition of Blaine Labs Inc. (“Blaine Labs”), a California-based pharmaceutical company. Alternate Health announced the closing of the Blaine Labs acquisition agreement in a press release on June 20, 2019. Since the transaction was closed midway through Q2, the Company’s financial results do not include the full three-month Q2 revenues of Blaine Labs.
 
Alternate Health expects an increase in revenue in Q3, since the quarter will include the full three-month period of Blaine Labs revenue. The Company also anticipates stronger results now that the agreement has closed, and the Company is not distracted with negotiation. Management can focus resources directly on generating revenues and launching new products.
 
“We are hard-at-work finalizing product formulations, negotiating with distributors and securing inventory as we combine the strengths of Blaine Labs and Alternate Health,” says Howard Mann. “We expect to see some movement in revenue for Q3 2019, with the full impact of our efforts taking effect in Q4 2019.”

A significant portion of Alternate Health’s operating expenses include non-cash or non-recurring expenses. Also, as noted above, the Q2 2019 only include approximately 2 months of Blaine Labs revenue. If we account for the extra month, Alternate Health would have been close to break even on cashflow.
 
Alternate Health benefitted from general reductions in professional fees, salaries and management fees as well, while the company streamlined and focused its efforts on securing and expanding revenue-producing assets. Alternate Health intends to continue focusing reaching greater profitability while generating strong revenue growth.